


ICES LIBRARY
© 1989

Volume 5, Number 4, 1989

HEALTH SCIENCES

PROTEINS

Structure, Function, and Genetics



Alan R. Liss, Inc., New York

DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

PROTEINS

Structure, Function, and Genetics

Editor-in-Chief
Cyrus Levinthal

Department of Biological Sciences • Columbia University • New York, New York

Executive Editor
George D. Rose

Department of Biological Chemistry • Hershey Medical Center, Pennsylvania State University • Hershey, Pennsylvania

Associate Editors

Thomas E. Creighton

Medical Research Council Laboratory of Molecular Biology, Cambridge, England

John Abelson

Division of Biology, California Institute of Technology, Pasadena, California

Robert L. Baldwin

Department of Biochemistry, Stanford University School of Medicine, Stanford, California

Herman J.C. Berendsen

Laboratory of Physical Chemistry, University of Groningen, Groningen, The Netherlands

David Botstein

Genentech Inc., South San Francisco, California

Ralph Bradshaw

Department of Biological Chemistry, University of California, Irvine, California

Jean-Michel Claverie

Institute Pasteur, Unite d'Informatique Scientifique, Paris, France

David Eisenberg

Molecular Biology Institute, University of California, Los Angeles, California

Donald M. Engelman

Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut

S. Walter Englander

Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania

Richard M. Fine

Department of Biological Sciences, Columbia University, New York, New York

Robert J. Fletterick

Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California

Lila M. Gierasch

Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas

Walter Gilbert

Biological Laboratories, Harvard University, Cambridge, Massachusetts

Nobuhiro Gō

Department of Chemistry, Faculty of Science, Kyoto University, Kyoto, Japan

Jonathan Greer

Computer Assisted Molecular Design Group, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois

David Davies

Section of Molecular Structure, N.I.A.M.D.D., National Institutes of Health, Bethesda, Maryland

William DeGrado

Central Research and Development Department, E.I. du Pont de Nemours and Company, Wilmington, Delaware

Editorial Board

Arnold T. Hagler

The Agouron Institute, La Jolla, California

Jan Hermans

Department of Biochemistry, University of North Carolina, Chapel Hill, North Carolina

Barry Honig

Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York

Leroy Hood

Division of Biology, California Institute of Technology, Pasadena, California

Wayne L. Hubbell

Jules Stein Eye Institute, University of California School of Medicine, Los Angeles, California

Michael N.G. James

Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada

Alwyn Jones

Department of Molecular Biology, Uppsala, Sweden

Arthur Karlin

Departments of Biochemistry and Neurology, College of Physicians and Surgeons, Columbia University, New York, New York

Martin Karplus

Department of Chemistry, Harvard University, Cambridge, Massachusetts

William Konigsberg

Department of Molecular Biophysics and Biochemistry, Yale University, School of Medicine, New Haven, Connecticut

Joseph Kraut

Department of Chemistry, University of California at San Diego, La Jolla, California

Robert Langridge

Computer Graphics Laboratory, Department of Pharmaceutical Chemistry, University of California, San Francisco, California

Eaton E. Lattman

Department of Biophysics, Johns Hopkins School of Medicine, Baltimore, Maryland

Dale L. Oxender

Center for Molecular Genetics, University of Michigan, Ann Arbor, Michigan

Alexander Rich

Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts

James Wells

Department of Biological Chemistry, Genentech, Inc., South San Francisco, California

Jane S. Richardson

Department of Biochemistry, Duke University Medical Center, Durham, North Carolina

Michael G. Rossmann

Department of Biological Sciences, Purdue University, West Lafayette, Indiana

Chris Sander

Biocomputing Programme, European Molecular Biology Laboratory, Heidelberg, Federal Republic of Germany

Robert Sauer

Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts

Robert Schleif

Department of Biology, Johns Hopkins University, Baltimore, Maryland

David Shortle

Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland

Paul Sigler

Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut

John A. Smith

Departments of Molecular Biology and Pathology, Massachusetts General Hospital, Boston, Massachusetts

Thomas A. Steitz

Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut

Lubert Stryer

Department of Cell Biology, Stanford University School of Medicine, Stanford, California

J. Craig Venter

Section of Receptor Biochemistry and Molecular Biology, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

Don Wiley

Department of Biochemistry and Molecular Biology, Harvard University, Cambridge, Massachusetts

Kurt Wüthrich

Institut für Molekularbiologie und Biophysik, Eidgenössische Technische Hochschule, Zürich, Switzerland

Authorization to photocopy items for internal or personal use of specific clients, is granted by Alan R. Liss, Inc. for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$00.50 per copy, plus \$00.25 per page is paid directly to CCC, 27 Congress Street, Salem, MA 01970, 0887-3585/89 \$00.50 + .25.

Proteins: Structure, Function, and Genetics (ISSN 0887-3585) is published by Alan R. Liss, Inc., 41 East 11th Street, New York, NY 10003.

Advertising inquiries should be addressed to: Alan R. Liss, Inc., Att. Advertising Sales Manager, 41 East 11th Street, New York, NY, 10003, (212) 475-7700.

Subscription price: Volumes 5&6, 1989, eight issues, \$190.00. **Special personal subscription rate** for 1989: \$75.00. For all 1989 subscriptions outside the U.S., please add \$32.00 postage. Subscriptions at the personal rate must be made by personal check, credit card, bank draft or money order. All subscriptions outside North America will be sent by air. Payment must be made in US dollars drawn on a US bank. **Change of address:** Please send to publisher six weeks prior to move; enclose present mailing label with change of address. **Claims for missing issues:** Claims cannot be honored beyond four months after mailing date. Duplicate copies cannot be sent to replace issues not delivered because of failure to notify publisher of change of address. **Cancellations:** Subscription cancellations will not be accepted after the first issue has been mailed. Exclusive agent in Japan: Igaku Shoin Limited, Foreign Department, 1-28-36 Hongo, Bunkyo-ku, Tokyo 113, Japan. ¥ 54,000 for Volumes 5-6. (Air Cargo Service Only).

Indexed by: BIOSIS Data Base • Cambridge Scientific Abstracts • Chemical Abstracts • Current Contents/Life Sciences-Science Citation Index (SCISEARCH) • Excerpta Medica • Index Medicus

Three-Dimensional Structure of a Fluorescein-Fab Complex Crystallized in 2-Methyl-2,4-pentanediol

James N. Herron,¹ Xiao-min He,¹ Martha L. Mason,¹ Edward W. Voss, Jr.,² and Allen B. Edmundson¹

¹Department of Biology, University of Utah, Salt Lake City, Utah 84112 and ²Department of Microbiology, University of Illinois, Urbana-Champaign, Illinois 61081

ABSTRACT The crystal structure of a fluorescein-Fab (4-4-20) complex was determined at 2.7 Å resolution by molecular replacement methods. The starting model was the refined 2.7 Å structure of unliganded Fab from an autoantibody (BV04-01) with specificity for single-stranded DNA. In the 4-4-20 complex fluorescein fits tightly into a relatively deep slot formed by a network of tryptophan and tyrosine side chains. The planar xanthyonyl ring of the hapten is accommodated at the bottom of the slot while the phenylcarboxyl group interfaces with solvent. Tyrosine 37 (light chain) and tryptophan 33 (heavy chain) flank the xanthyonyl group and tryptophan 101 (light chain) provides the floor of the combining site. Tyrosine 103 (heavy chain) is situated near the phenyl ring of the hapten and tyrosine 102 (heavy chain) forms part of the boundary of the slot. Histidine 31 and arginine 39 of the light chain are located in positions adjacent to the two enolic groups at opposite ends of the xanthyonyl ring, and thus account for neutralization of one of two negative charges in the haptenic dianion. Formation of an enol-arginine ion pair in a region of low dielectric constant may account for an incremental increase in affinity of 2-3 orders of magnitude in the 4-4-20 molecule relative to other members of an idiotypic family of monoclonal antifluorescyl antibodies. The phenyl carboxyl group of fluorescein appears to be hydrogen bonded to the phenolic hydroxyl group of tyrosine 37 of the light chain. A molecule of 2-methyl-2,4-pentanediol (MPD), trapped in the interface of the variable domains just below the fluorescein binding site, may be partly responsible for the decrease in affinity for the hapten in MPD.

Key words: antifluorescyl monoclonal antibody, high-affinity binding site, effects of MPD on hapten binding

INTRODUCTION

The antifluorescein system is well suited for studying the molecular basis of antigenic specificity because it offers both a wide range of binding affinities (10^5 - 10^{10} M⁻¹), and a variety of experimental

techniques for correlating antigen binding affinities, kinetics, and thermodynamics.¹⁻⁹ Furthermore, it has been possible to develop a family of idiotypically cross-reactive antibodies in which individual monoclonals vary in affinity over a 1000-fold range.⁹ Amino acid sequences recently determined for eight of these antibodies in one of our laboratories (E.W.V.) show that at least six were derived from the same germline variable genes. Thus, the antifluorescein idiotype family can be used to further the understanding of both idiotypic and affinity maturation. In this report, we describe the three-dimensional structure of a complex of dianionic fluorescein with the antigen-binding fragment from the antibody (4-4-20) with the highest affinity in this idiotype family.

The 4-4-20 monoclonal is an IgG_{2a} (κ) antibody that binds fluorescein with an association constant of 3.4×10^{10} M⁻¹ in aqueous solution. This affinity decreases 300-fold in 47% (v/v) 2-methyl-2,4-pentanediol (MPD), the solvent used for cocrystallization of the 4-4-20 Fab with fluorescein hapten.⁵ The antibody is a highly specialized molecule that does not cross-react with rhodamine compounds.^{1,6} In the formation of a complex with the 4-4-20 antibody, fluorescein satisfied criteria for a site-filling ligand, with the xanthyonyl ring behaving as the "immunodominant" moiety.⁶ Despite its relatively large size and distinctive chemical features, fluorescein induces a diverse immune response when injected as a conjugate with keyhole limpet hemocyanin (KLH).^{1,7-9} Interpretation of binding studies have sometimes been ambiguous with heterogeneous populations of antibodies. It therefore seemed appropriate to determine the mode of binding in a single molecular species, particularly one with high affinity for fluorescein.

This crystal system affords a rare opportunity to consider both the structural features responsible for high-affinity binding and the effects of solvent in lowering that affinity. The complex will also be ex-

Received January 20, 1989; revision accepted March 24, 1989.

Address reprint requests to A.B. Edmundson, Department of Biology, University of Utah, Salt Lake City, UT 84112.

James N. Herron's present address is Department of Pharmaceutics, University of Utah, Salt Lake City, UT 84112.

amined to assess the influence of the carrier protein (KLH) on the location and orientation of the hapten in the combining site. In the preparation of the immunogen, molecules of the isothiocyanate derivative of fluorescein amine (isomer I) were coupled to KLH, with the principal reactions presumed to involve the ϵ -amino group of lysine side chains. The 4-4-20 hybridoma was obtained by fusion of hyper-immunesplenocytes stimulated with the fluorescein-KLH conjugate.

The present work adds to previous crystallographic studies of complexes in which small molecules were diffused into crystals of human and murine immunoglobulin fragments with binding sites shaped like cavities or shallow depressions.¹⁰⁻¹⁵ These studies have helped define the molecular basis of low- and medium-affinity interactions and have provided the background to broaden our understanding of antigenic specificity. Block-end types of interactions over large external surfaces have been studied in cocrystals of Fab molecules and protein antigens like lysozyme and influenza neuraminidase.¹⁶⁻¹⁹ Antibodies binding DNA have grooves as potential combining sites, and cocrystals of Fabs and oligodeoxynucleotides are currently being subjected to X-ray analyses.²⁰⁻²³ The structure of an unliganded Fab (J539) with specificity for galactan in carbohydrates has also been determined.²⁴ A model for the binding of the ligand was proposed on the basis of solution studies and the structure of the combining site.

Recently, a single-chain antigen-binding protein²⁵ was constructed to simulate the Fv fragment of the 4-4-20 antibody (an Fv fragment consists of the "variable" domains of the heavy and light chains). The three-dimensional structure of the 4-4-20 Fab should prove very useful in assessing the properties and applications of the single chain protein.

MATERIALS AND METHODS

Preparation of Fluorescein-Fab Complex

Procedures for the isolation and purification of the 4-4-20 monoclonal antibody and fluorescein-Fab complex were described in a previous article.⁵ In outline the Fab fragments were prepared by hydrolysis of fluorescein-IgG complexes with papain. Liganded Fabs were purified by chromatofocusing on 15 ml Pharmacia PBE 94 columns, with a linear pH gradient of 9 to 6 formed with Pharmacia Polybuffer 96. Because of potential destructive effects of dye-sensitized photooxidation by free fluorescein, it was necessary to protect the liganded protein from light at all stages of the procedures. Columns, tubes, and vessels used in affinity chromatography, chromatofocusing, dialysis, enzymatic hydrolysis, and crystallization trials were all covered with aluminum foil. All manipulations and transfers were carried out in reduced light. Under such precautions

the liganded Fab was eluted from the chromatofocusing column as a single component with a *pI* of 7.2.

After dialysis against 50 mM sodium phosphate, pH 7.2, the solution of the fluorescein-Fab complex was concentrated to 25 mg/ml by ultrafiltration (the acceptable range for crystallization was 10-30 mg/ml). The complex was crystallized by a batch method in an environment with strict light and temperature (12-14°C) control. Graded aliquots of MPD were added to 40 μ l samples of the liganded protein in flat-bottomed glass vials. Crystals appeared in 2 days with final MPD concentrations of 38-60% (v/v), the optimum being ~47%. Bladed crystals suitable for X-ray analysis grew to dimensions of 0.6 \times 0.35 \times 0.3 mm (l \times w \times d) in 1-2 months. Green fluorescence, attributable to the dissociation of fluorescein from the complex in MPD, was observed in each crystallization tube.

Collection of X-Ray Diffraction Data

The fluorescein-Fab complex crystallized in the triclinic space group *P1*, with $a = 58.3$, $b = 43.9$, and $c = 42.5$ Å; $\alpha = 82.1$, $\beta = 87.3$, and $\gamma = 84.6^\circ$.⁵ Crystals disintegrated at temperatures $>22^\circ\text{C}$, but were mechanically stable even in the X-ray beam when the ambient temperature was maintained at 12-14°C. Temperature instability of the complex in MPD had also been noted in solution.⁵ For example, irreversible increases in the standard free-energy changes (ΔG°) in the liganded IgG and Fab molecules occurred in 40% MPD at relatively low temperatures (transition temperature of 30°C).

A single crystal was used to collect X-ray diffraction data to 2.7 Å resolution with a Nicolet P21 diffractometer operated at 40 kV and 35 mA (CuK α radiation). The data set included 11,116 unique reflections, of which 9120 (82.0%) were observed at intensity levels >1.5 standard deviations (based on counting statistics).

Determination of the Three-Dimensional Structure of the Liganded Fab

The fluorescein-Fab complex crystallized in the same space group (*P1*) as the unliganded Fab of the BV04-01 IgG_{2b} autoantibody, with specificity for single-stranded DNA.^{5,26} Unit cell dimensions for the two crystals were nearly identical and one of us (X-M.H.) found by molecular replacement methods²⁷⁻³⁰ that the proteins were in the same orientations in these unit cells. With the refined 2.7 Å structure of the BV04-01 Fab as starting model, the orientation of the 4-4-20 Fab was determined more accurately with rotation function programs.

Crystallographic refinement^{31,32} of the structure was initiated with the X-ray diffraction data⁵ for the 4-4-20 Fab and the atomic model of the BV04-01 Fab.^{22,23} After 30 cycles of refinement with 2.7-6.0 Å data (8304 reflections), the amino acid sequences

TABLE I. Refinement Data

	Actual rms deviation	Target value
Average ΔF^*	46.6	
R -factor	0.215	
$\langle B \rangle$ in \AA^2 †	15.5	
No. of reflections, $I > 1.5 \sigma(I)$ ‡	8304	
Root mean square (rms) deviations		
From ideal distance (\AA)		
Bond distance	0.028	0.03
Angle distance	0.055	0.04
Planar 1-4 distance	0.032	0.03
Hydrogen bond distance§	0.132	0.05
rms deviation from planarity (\AA)	0.014	0.025
rms deviation from ideal chirality (\AA^3)	0.210	0.150
rms deviation from permitted contact distances (\AA)		
Single torsion contacts	0.280	0.500
Multiple torsion contacts	0.400	0.500
Possible hydrogen bond	0.409	0.500
rms deviation from ideal torsion angles ($^\circ$)		
For prespecified ϕ, ψ angles	30.8	15.0
For planar group (0 or 180)	6.3	3.0
For staggered group (± 60 or 180)	26.9	15.0
For orthonormal group (± 90)	28.1	15.0

*The weight for the structure factor refinement was obtained from the equation $w = (1/\sigma)^2$, where $\sigma = 40 - 278 \times [\sin(\theta)/\lambda - 1/6]$.

†Average temperature factor.

‡Resolution limits of 2.7–6.0 \AA .

§Explicit hydrogen bonds for β -pleated sheets.

of the light and heavy chains were altered to correspond to those of the 4-4-20 Fab.³⁴ The model of the 4-4-20 Fab was improved through alternating cycles of refinement and interactive model building on an Evans and Sutherland PS300 graphics system with the FRODO program.^{35,36} Polypeptide backbones and amino acid side chains were fitted to $2F_o - F_c$ maps, in which F_o and F_c were observed and calculated structure factors. Fluorescein was located in a $\Delta F (F_o - F_c)$ map, for which the phase angles were calculated from the refined atomic model of the protein (atomic coordinates for fluorescein were omitted). The ligand-protein complex was subjected to additional cycles of refinement until the R factor ($\Sigma \|F_o - F_c\| / \Sigma \|F_o\|$) began to plateau at its current value of 0.180 (before idealization of bond lengths and angles; 0.215 after).

RESULTS

Description of the Three-Dimensional Structure of the Fluorescein-Fab Complex

The results of the crystallographic refinement of the complex are presented in Table I. This structure could be refined very quickly because of the great similarities with the structure of the unliganded BV04-01 Fab.

Figure 1 contains the three-dimensional "cage" electron density to which a skeletal model of fluorescein was fitted by interactive computer graphics. The torsion angle measured between the xanthonyl and benzoyl rings was 73° in the bound hapten.

An αC skeletal model of the 4-4-20 Fab is shown as a stereo pair in Figure 2, with a model of fluorescein codisplayed in the binding site. Tracings of the αC chains of the 4-4-20 and BV04-01 Fabs are superimposed in Figure 3. Details of the structures of the ligand and combining site are presented in Figure 4 (skeletal models). Solvent-accessible surfaces³⁷ are illustrated in Figure 5. Amino acid sequences³⁴ for the hypervariable regions are listed in Figure 6.

Polypeptide chains could be traced unambiguously in both the light and heavy chains of the 4-4-20 complex. Significantly, the third hypervariable loop, which was difficult to follow in the heavy chain of the BV04-01 Fab, was well defined in the fluorescein-Fab complex. In the presence of ligand, constituents of this loop were found to have small temperature factors (B values), characteristic of regions with low mobility.

Comparison of the Structures of the 4-4-20 and BV04-01 Fabs

The 4-4-20 Fab is an extended molecule in which the pseudotwofold axes between the pairs of variable and constant domains are nearly colinear (i.e., the measured "elbow bend" angle between the two pseudodiads is 171°). Except for the third hypervariable loops, in which the 4-4-20 heavy chain is shorter than the BV04-01 sequence by three residues, the αC tracings are remarkably similar in the two proteins. This similarity is readily understand-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.